948 - Recent “Expert Panels” Could Undermine the FDA’s Credibility
About this episode:
The FDA has long convened scientifically rigorous advisory committees to review data and offer recommendations for regulating a range of food and drug products. However, it has recently pulled back and leaned heavily into ad-hoc “expert panels” that are not held to the same standards. In this episode: Caleb Alexander, an epidemiologist and drug safety expert who has served on over a dozen FDA advisory committees, raises concerns about the lack of transparency and accountability in these new panels and suggests that their lax standards might undermine the agency’s credibility.
Guest:
Dr. G. Caleb Alexander, MS, is a practicing internist and drug safety expert at the Johns Hopkins Bloomberg School of Public Health.
Host:
Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health.
Show links and related content:
-
The FDA’s pivot from ad comms to ‘expert’ panels is bad medicine—STAT
-
An FDA panel spread misinformation about SSRI use in pregnancy, alarming doctors—NPR
Transcript Information:
Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel.
Contact us:
Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website.
Follow us:
-
Here's our RSS feed
Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.
More episodes from "Public Health On Call"
Don't miss an episode of “Public Health On Call” and subscribe to it in the GetPodcast app.
